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Abstract: Telavancin, a novel lipoglycopeptide with rapid concentration-dependent bactericidal 
effects, is a semisynthetic derivative of the glycopeptide, vancomycin. Telavancin has a dual 
mechanism of action, ie, inhibition of peptidoglycan polymerization and disruption of the bacte-
rial membrane. It has linear pharmacokinetics, rapid bactericidal killing, and broad spectrum 
activity against Gram positive bacteria, including methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant S. aureus. Phase II and III clinical trials for complicated 
skin and skin structure infections have shown telavancin to have similar efficacy and tolerability 
to that of vancomycin and standard anti-staphylococcal β-lactams plus vancomycin. In Phase 
II trials, there was a significant difference in eradication of MRSA between groups, ie, telavancin 
therapy 92% and standard therapy (vancomycin, nafcillin, oxacillin, or cloxacillin) 68% 
(P  0.05). In Phase III trials, among clinically evaluable patients who had MRSA isolated at 
baseline, the overall therapeutic response was higher in patients treated with telavancin than in 
patients treated with vancomycin (89.9% versus 84.7%; 95% CI -0.3, 10.5). Also, the efficacy 
of telavancin was not inferior to that of vancomycin for the treatment of complicated skin and 
skin structure infections in the clinical trials.
Keywords: telavancin, methicillin-resistant Staphylococcus aureus, MRSA, complicated skin 
and skin structure infections, Gram-positive bacteria
Introduction
Staphylococcus is the leading cause of bacterial infections involving the blood stream, 
skin, and soft tissue. After worldwide use of penicillin, which was highly effective 
against Staphylococcus aureus during the 1940s, penicillin-resistant S. aureus was 
reported. Methicillin was introduced in 1959 to combat this penicillinase-producing 
bacterium, and beta-lactamase-resistant antibiotics, including methicillin, nafcillin, 
and the cephalosporins, were in common use by the late 1950s and early 1960s. 
By 1961, the first isolate of methicillin-resistant S. aureus (MRSA) had been  identified, 
and it soon became a major cause of hospital-associated (nosocomial) infections.1 
In the US, the mortality rate associated with invasive MRSA infections has been 
estimated at 20%, and these infections are probably the leading cause of death by any 
single infectious agent in that country.1 Fatalities resulting from these infections are 
estimated to surpass those caused by human immunodeficiency virus/acquired 
 immunodeficiency syndrome.1,2 MRSA is a global public health problem widely 
encountered in health care practices.3–6 Today MRSA is both a nosocomial and 
community-acquired isolate, accounting for more than 50% of S. aureus isolates in 
intensive care units in the US.7,8
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S. aureus produces Panton–Valentine leucocidin, a toxin 
which is now an established virulence factor linked to 
community-acquired MRSA strains.9 Panton–Valentine 
leucocidin has been associated with specific human infections 
in skin and soft tissues.10 Infection with community-acquired 
MRSA is most commonly associated with skin and soft tissue 
infection, such as cellulitis, boils, and furuncles (abscesses) 
which, if untreated, may lead to osteomyelitis or necrotizing 
fasciitis.11,12 In addition, S. aureus toxins may result in toxic 
shock syndrome.13
Hospital-associated MRSA infection requires aggressive 
antimicrobial therapy, and is associated with increased mor-
tality among hospitalized patients.14,15 Risk factors for noso-
comial MRSA infection have been well established, and 
include dialysis, recent hospitalization or surgery, residence 
in a long-term care facility, prolonged antimicrobial therapy, 
and indwelling percutaneous medical devices or catheters.11 
This paper reviews the published clinical data on the role of 
telavancin in the treatment of complicated skin and soft tissue 
infections.
Description and mechanism  
of action
Telavancin, a novel lipoglycopeptide with rapid  concentration- 
dependent bactericidal effects, is a semisynthetic derivative 
of the glycopeptide, vancomycin. Telavancin has a lipophilic 
side chain (decylaminoethyl), as well as a negatively charged 
phosphonomethyl aminomethyl group.16,17 The lipophilic 
side chain has been hypothesized to increase the membrane-
anchoring properties of telavancin, leading to enhanced 
affinity for lipid II, a bacterial membrane-anchored cell 
wall precursor. Lipid II is essential for bacterial cell wall 
 biosynthesis. The liposaccharide element inhibits transgly-
cosylase enzymes, which are directly responsible for the 
production of immature peptidoglycan. Peptidoglycan is a 
polymer consisting of sugars and amino acids that form a 
mesh-like layer outside the plasma membrane of bacteria, 
forming the cell wall. The polar substituent (phosphonom-
ethyl aminomethyl) appears on the resorcinol-like 4′-position 
of amino acid 7 of the telavancin structure, and this hydro-
philic side chain is believed to increase distribution in the 
body and reduce potential nephrotoxicity by promoting rapid 
clearance.18–21
Telavancin possesses a unique dual mechanism of action. 
Like vancomycin, telavancin inhibits transglycosylate 
 activity and bacterial cell wall synthesis by interfering with 
the polymerization and cross-linking of peptidoglycan, 
a  process that involves binding to peptidoglycan precursors 
 terminating in d-alanyl-d-alanine.22 Unlike vancomycin, 
telavancin also binds to the bacterial membrane, disrupting 
its functional integrity. This action is mediated by targeted 
interaction with the cell wall precursor, lipid II. Thus, tela-
vancin has a dual mechanism of action, ie, inhibition of 
peptidoglycan polymerization and disruption of the bacterial 
membrane.20–25
Bactericidal effects
Preclinical studies showed that telavancin has a more 
potent antimicrobial effect against methicillin-sensitive 
S. aureus (MSSA) and MRSA than do the beta-lactams, 
linezolid, and vancomycin. For example, in a neutropenic 
mouse thigh model of infection, telavancin was found to be 
four times more potent than vancomycin against MRSA and 
43 times more potent than nafcillin against MSSA. This 
higher potency against both MRSA and MSSA was also 
documented in immunocompetent animal models. Peak and 
trough serum levels of telavancin achieved in the FAST 
1 study were 264 and 16 times greater than the minimum 
inhibitory concentration (MIC)
90
 values, respectively, for 
both MSSA and MRSA strains. These findings extend to 
other resistant Gram-positive cocci and methicillin-resistant 
coagulase-negative Staphylococci.26–28
Telavancin exerts concentration-dependent bactericidal 
activity against Gram-positive organisms in vitro, includ-
ing a wide range of clinical isolates that are resistant to other 
antibiotics. Telavancin affects bacterial plasma membrane 
function, including membrane potential depolarization, and 
increases permeability, and these actions are observed at 
higher but clinically achievable concentrations. This multi-
functional mechanism of action accounts for the rapid bac-
tericidal activity of telavancin, as well as its activity against 
bacterial strains with reduced susceptibility to vancomycin, 
such as glycopeptide-intermediate S. aureus, heterogenous 
glycopeptide-intermediate S. aureus, and vancomycin- 
resistant S. aureus.12,16,22,26–28
Like other glycopeptide antibiotics, telavancin is also 
effective against Gram-positive anaerobes, including 
Clostridium, Lactobacillus, Propionibacterium, Peptostrep-
tococcus, and Corynebacterium species at concentrations of 
2 µg/mL or lower. In vitro studies have shown that telavancin 
is bactericidal against clinically important Gram-positive 
bacteria, including drug-resistant strains, such as MRSA, 
vancomycin-intermediate S. aureus, and penicillin-resistant 
pneumococci.25
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Pharmacokinetics
The pharmacokinetic parameters of telavancin have been 
studied in mice, rats, dogs, and monkeys. Linear kinetics 
were seen in the telavancin half-life after prolonged dosing 
at 13 weeks in rats. The primary route of elimination for 
telavancin is renal.29 The long half-life (7–9 hours) and 
postantibiotic effect (4–6 hours) allows for once-daily 
intravenous administration. The drug is not available in 
oral form.26,27
Pharmacokinetic studies of telavancin were performed 
during Phase I clinical trials on healthy volunteers and 
selected subjects with renal or hepatic impairment. When 
infused intravenously over a period of 30–120 minutes, 
telavancin demonstrated linear pharmacokinetics within a 
dose range of 7.5–15 mg/kg. Steady state of telavancin in 
blood was achieved by day 3 or 4, with no evidence of 
tissue accumulation. Telavancin elimination is renal at a 
dose $5 mg/kg, and its half-life is between 6.9–9.1 hours in 
healthy subjects.30
The recommended daily therapeutic dosage of telavancin 
is considered to be 10 mg/kg/day in patients with a creatinine 
clearance above 50 mL/min. The observed half-life of tela-
vancin at this dosage was 7–9 hours. The plasma concentra-
tion of telavancin increases in a linear fashion proportional 
to dose, without any clinically important drug accumulation.30 
These data further support the recommendation for once-
daily dosing.
For patients with a creatinine clearance of 30–50 mL/min, 
75% of the dose (7.5 mg/kg) is recommended, while for 
patients whose creatinine clearance is less than 30 mL/min, 
an increased dosing interval up to 48 hours is recommended.31 
Based on an in vitro model, telavancin is not recommended 
in patients with renal failure on hemodialysis.32 The phar-
macokinetics of a single 10 mg/kg dose of telavancin in 
eight patients with significantly compromised liver function 
(Child–Pugh Class B) did not show any significant differ-
ence between normal subjects and patients with moderate 
hepatic impairment.33 Telavancin has a short distribution 
phase,  followed by a decrease at a rate proportional to its 
initial serum concentration (monoexponential decline). 
Age 65 years and older did not affect telavancin clearance, 
but there was a more extensive volume of distribution and 
longer half-life.34
Serum peak and trough concentrations were measured in 
Phase II clinical trials. Patients older than 18 years were 
administered the study medication for at least 4–14 days. 
In the first trial, 48 patients receiving telavancin 7.5 mg/kg 
once daily had a mean peak of 66 ± 12 µg/mL and a trough 
of 4 ± 0.8 µg/mL. In the second trial, 47 patients receiving 
telavancin 10 mg/kg once daily had a mean peak of 
82.2 ± 27.3 µg/mL and a trough of 8.66 ± 7.28 µg/mL.26,27
In one study of tissue penetration by telavancin, nine 
healthy subjects aged 21–46 years received telavancin 7.5 mg/
kg once daily for 3 days, and serum levels were evaluated on 
the third day. The steady-state area under the curve in blister 
fluid was 40% of its plasma concentration, ie, enough to 
eliminate pathogens.35 In a study in 20 healthy subjects, tela-
vancin showed good penetration into the epithelial lining fluid, 
yielding a fluid:plasma concentration ratio of 0.75. The mean 
concentration of telavancin in epithelial lining fluid was 2–8-
fold higher than the MIC
90
 value.36,37 Levels of telavancin were 
observed to be higher in alveolar macrophages than in epi-
thelial lining fluid, and were not affected by the presence of 
lung surfactant, which is an important consideration in the 
treatment of pneumonia.29,35–38 Telavancin showed 93% protein 
binding in human plasma compared with approximately 50% 
for vancomycin. Plasma protein had minimal impact on tela-
vancin activity against staphylococci and streptococci.16
Rationale for a new 
antistaphylococcal antimicrobial
Vancomycin remains the standard treatment for serious 
MRSA infections, and is now the second most common 
antibiotic used in hospitals. In 50 years of use, only six clinical 
MRSA strains with vancomycin resistance have been 
 identified, but there are several concerns about vancomycin, 
ie, heteroresistance in MRSA (small numbers of organisms 
have high vancomycin MICs), “MIC creep”, which describes 
an increase in recent years in numbers of clinical isolates of 
both MRSA and MSSA with vancomycin MIC $ 2 µg/mL 
(strains now considered only immediately sensitive to van-
comycin), and prolonged MRSA bacteremia in many patients 
despite adequate vancomycin treatment, as indicated 
by trough levels of 15–20 µg/mL. The standard regimen 
of intravenous vancomycin is 1 g every 12 hours. In cases of 
vancomycin failure, the options are linezolid 600 mg every 
12 hours, daptomycin 6–8 mg/kg/day,  clindamycin 600 mg 
every eight hours, or trimethoprim-sulfamethoxazole 
10/50 mg/kg/day.3,39–41
Active antibiotics for nosocomial MRSA strains are 
usually limited to vancomycin, linezolid, daptomycin, cef-
taroline, and tigecycline. There is a broader susceptibility 
in USA300 strains, which may be susceptibleto trimethoprim-
sulfamethoxazole, minocycline, and clindamycin. 
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USA300 strains continue to dominate community-acquired 
forms of S. aureus infection, but are found with increasing 
frequency in hospital settings and are increasingly resistant 
to antibiotics, including tetracycline and clindamycin.3
For outpatient treatment of community-acquired MRSA 
infections, trimethoprim-sulfamethoxazole, minocycline, 
doxycycline, or clindamycin may be appropriate, depend-
ing on the severity of the illness and susceptibility of the 
organism.7,42,43
Telavancin, delbavancin, and oritavancin are vancomycin 
derivatives that kill S. aureus rapidly in a concentration-
dependent manner in vitro.25 Carbapenems and cepha-
losporins have been developed against MRSA, and two 
cephalosporins, ceftobriprole and ceftaroline, have been 
shown to be clinically effective for treatment of skin and 
skin structure infections. Vancomycin derivatives and anti-
MRSA beta-lactams can only be administered intravenously. 
 However, orally bioavailable oxazolidinones active against 
MRSA are in development.44–47
Clinical indications
In clinical trials, telavancin has been shown to be efficacious 
for the treatment of complicated skin and skin structure 
infections.26,27,48
Phase II trials
In 2004, Stryjewski et al conducted a randomized, double-
blind, controlled Phase II clinical trial in the US and 
South Africa, in which 167 patients aged older than 18 years 
and with a diagnosis of complicated skin or soft tissue 
infection caused by a suspected or confirmed Gram-positive 
organism, were randomized to receive either telavancin 
7.5 mg/kg once daily intravenously (n = 84) or standard 
therapy of vancomycin 1 g every 12 hours, nafcillin or 
 oxacillin 2 g every six hours, or cloxacillin 0.5–1 g every 
six hours (n = 83). They were on treatment for 4–14 days. 
As Table 1 shows, for all treated patients, the cure rate was 
79% and 80% for the telavancin and standard therapy 
groups, respectively. In the clinically evaluable population, 
92% of the telavancin group and 96% of the standard 
therapy group were cured. In the microbiologically evalu-
able population, 93% of the telavancin group and 95% of 
the standard therapy group were cured. For the patients in 
whom S. aureus was isolated at baseline, cure was achieved 
at the test-of-cure evaluation in 80% of the telavancin group 
and 77% of the standard therapy group; in patients with 
MRSA at baseline, cure was achieved in 82% and 69% of 
the telavancin group and standard therapy group, respec-
tively. At the test-of-cure evaluation,  successful eradication 
of pathogens was seen in 80% and 82% of the telavancin 
group and standard therapy group, respectively. In patients 
infected with MRSA, test-of-cure evaluation was 84% for 
patients treated with telavancin and 74% for those treated 
with standard therapy. In all tests, the P value was more 
than 0.05, and no difference was statistically significant 
(see Table 1).26
Stryjewski et al also conducted a randomized, double-
blind, active control, parallel Phase II trial in two centers in 
the US and seven centers in South Africa in 2005. They 
recruited patients .18 years of age with complicated skin 
and soft tissue infection caused by suspected or confirmed 
Gram-positive pathogens. The objective of the study was to 
compare the safety and efficacy of telavancin 10 mg/kg once 
daily for the treatment of complicated skin and soft tissue 
infection with that of standard therapy (vancomycin 1 g every 
12 hours or nafcillin or oxacillin 2 g/day or cloxacillin 0.5–1 g 
every six hours) for 4–14 days. They randomized a total of 
195 patients (telavancin therapy group = 100, standard 
therapy group = 95; see Table 1). A cure rate was achieved 
at test-of-cure in 82% of the telavancin group and 85% of 
the standard therapy group (P = 0.37). In the clinically evalu-
able populations, 96% in the telavancin group and 94% in 
the standard therapy group (P = 0.53) were cured at test-of-
cure evaluation. In the microbiologically evaluable population 
at test-of-cure, a cure was obtained in 97% in the telavancin 
group and 93% in the standard therapy group (P = 0.37). In 
microbiologically evaluable patients with S. aureus at base-
line, 96% of those in the telavancin group and 90% of those 
in the standard therapy group were cured (P = 0.36). The 
same rates (96% and 90% for telavancin and standard therapy, 
respectively, P = 0.42) were observed for patients with 
MRSA. At test-of-cure, S. aureus eradication was higher in 
patients receiving telavancin (92% versus 78%, P = 0.07, not 
statistically significant). In patients infected with MRSA, 
eradication rates were significantly higher in the telavancin 
group (92% versus 68%, P = 0.04; see Table 1). In total, 
pathogen eradication was greater in patients receiving tela-
vancin (94% versus 83%, P = 0.06, not statistically signifi-
cant; see Table 1).27
Phase III clinical trials
In 2008, Stryjewski et al reported the results of the ATLAS 
(Assessment of TeLAvancin in Skin and skin structure 
 infections) study. Two identical parallel, randomized, 
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 double-blind, active-controlled Phase III clinical studies with 
a prespecified pooled analysis design (studies 0017 and 0018) 
from January 2005 to June 2006 were carried out in 129  centers 
in 21 countries. They randomized men and nonpregnant 
women aged older than 18 years with a diagnosis of 
 complicated skin and soft tissue infections that warranted more 
than seven days of parenteral antibacterial therapy. Patients 
received either intravenous telavancin 10 mg/kg every 
24 hours or vancomycin 1 g every 12 hours for 4–14 days. 
The dose of telavancin was adjusted for patients with moderate 
to severe renal insufficiency, ie, 7.5 mg/kg every 24 hours for 
patients who had a creatinine clearance of 30–50 mL/min, and 
10 mg/kg every 48 hours for creatinine clearance 30 mL/min 
(including patients on hemodialysis). No supplemental tela-
vancin therapy was administered after dialysis. A total of 
1867 patients were randomized and received at least one 
dose of study medication, with 928 receiving telavancin and 
939 patients receiving vancomycin. More than two-thirds of 
patients were recruited for the study in the US. The 95% 
confidence intervals (CI) for the treatment difference between 
the two regimens from each study overlapped, enabling pool-
ing of the data. In the clinically evaluable population, the 
clinical cure rates were 88.3% and 87.1% for the telavancin- 
and vancomycin-treated groups, respectively (95% CI for the 
difference in cure rates, -2.1, 4.6). Of the clinically evaluable 
patients infected with MRSA at baseline, 90.6% of the patients 
in the telavancin group and 86.4% of the patients in the van-
comycin group were cured (95% CI for the difference in cure 
rates, -1.1, 9.3). Among microbiologically evaluable patients 
at baseline, S. aureus were eradicated in 89.8% and 87.3% of 
the  telavancin group and standard therapy group, respectively 
(95% CI for the difference in cure rates, -1.4, 6.2). Among 
Table 1 Summary of the clinical results of telavancin or standard therapy for the treatment of complicated skin and soft tissue 
infections
Name of study Phase II, FAST 1a Phase II, FAST 2 Phase III, ATLASb
Treatment Telavancin  
7.5 mg/kg
Standard  
therapyc
Pd Telavancin  
10 mg/kg
Standard  
therapy
P Telavancin  
7.5 mg/kg
Vancomycin  
1 g/12 hours
Difference  
in cure rate  
(95% CI for  
the difference)e
Number of patients 84 83 – 100 95 – 928 939 –
Mean age of subjects 44.6 ± 13.9 44.3 ± 13.5 – 44.7 ± 13.7 42.3 ± 10.9 0.18 48.8 ± 16.6 48.7 ± 16.6 –
All treated  
achieved cure
66/84 (79%) 66/83 (80%) 0.53 82/100 (82%) 81/95 (85%) 0.37 710/928  
(76.5%)
697/939  
(74.2%)
2.3 (-1.6, 6.2)
Infected with 
S. aureus,  
achieved cure
40/50 (80%) 40/52 (77%) 0.80 48/50 (96%) 37/41 (90%) 0.36 – – –
Infected with MRSA,  
achieved cure
18/22 (82%) 18/26 (69%) 1.00 25/26 (96%) 17/19 (90%) 0.42 252/278  
(90.6%)
260/301  
(86.4%)
4.1 (-1.1, 9.3)
Clinically evaluable,  
achieve cure
66/72 (92%) 66/69 (96%) 0.53 74/77 (96%) 72/77 (94%) 0.53 658/745  
(88.3%)
648/744  
(87.1%)
1.2 (-2.1, 4.6)
Microbiologically  
evaluable, achieved  
cure
52/56 (93%) 53/56 (95%) 0.79 62/64 (97%) 53/77 (93%) 0.37 – – –
Microbiological  
eradication of Gram  
positive pathogens  
at TOCf
44/56 (80%) 46/56 (82%) 0.53 46/50 (92%)* 32/41 (78%)* 0.07 473/527  
(89.8%)
468/536  
(87.3%)
(-1.4, 6.2)
Microbiological  
eradication of MRSA,  
at TOC
16/19 (84%) 14/19 (74%) 0.83 24/26 (92%) 13/19 (68%) 0.04 250/278  
(89.9%)
257/301  
(85.4%)
(-0.9, 9.8)
Adverse events 47/84 (56%) 50/83 (60%) – 56/100 (56%) 54/95 (57%) 1.0 735/928 
(79%)
676/939  
(72%)
–
Severe adverse  
events
3/84 (4%) 6/83 (7%) – 6/100 (6%) 4/95 (4%) – 69/928 
(7%)
42/939 (4%) –
Notes: aFAST: Name of study; bATLAS: Assessment of TeLAvancin in Skin and skin structure infections; cStandard therapy: vancomycin 1 g every 12 hours, nafcillin 
or oxacillin 2 g/day or cloxacillin 0.5–1 g every six hours; dP values are from Bernard’s unconditional test of superiority; indeterminate values were excluded from the 
calculations; e95% CI for the difference between the proportion of patients who were cured by telavancin and by vancomycin; *In this evaluation only Staphylococcus aureus 
pathogen was considered.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; TOC, test-of-cure; CI, confidence intervals.
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microbiologically evaluable patients with MRSA isolates at 
baseline, eradication was 89.9% and 85.4% for telavancin and 
vancomycin treatment groups, respectively (95% CI for the 
difference in cure rates, -0.9, 9.8; see Table 1). With regard to 
overall therapeutic response, patients were cured and patho-
gens were eradicated in 88.6% and 86.2% in the telavancin 
and vancomycin groups, respectively (95% CI for the differ-
ence in cure rates, -1.6, 6.4). Among clinically evaluable 
patients who had MRSA isolated at baseline (n = 579), the 
overall therapeutic response was higher in patients treated with 
telavancin than in patients treated with vancomycin (89.9% 
versus 84.7%; 95% CI: -0.3, 10.5). The median duration of 
therapy was approximately one day shorter with telavancin 
than with vancomycin.48
In 2009, Wilson et al compared the results of telavancin 
versus vancomycin in patients with postsurgical complicated 
skin and soft tissue infection, particularly those infected 
with MRSA, who were treated in the ATLAS study.24 Of 
1867 randomized patients, 194 had complicated skin and 
soft tissue infection related to a recent surgical procedure 
(all-treated population, telavancin n = 101, vancomycin 
n = 93). In 49% of these patients, S. aureus was isolated and 
identified as the pathogen, including 28% patients infected 
with MSSA and 22% infected with MRSA. Trends favoring 
telavancin in clinical cure rates were observed in all analyzed 
populations. Those trends were strongest in the MRSA and 
MSSA subsets, but they did not reach statistical significance. 
Mean and median duration of treatment was 10 days in both 
groups.24
The ATLAS study contained one of the largest subsets 
of patients with complicated skin and soft tissue infection of 
any randomized, double-blind study to date, including those 
with documented MRSA infections. Not unexpectedly, this 
subset of patients with skin and soft tissue infection had a 
higher incidence of comorbid conditions compared with the 
overall ATLAS population. Nevertheless, telavancin proved 
at least as efficacious as vancomycin for treatment of patients 
with skin and soft tissue infections, including those infected 
with MRSA. The relatively small numbers of patients in the 
subgroups could be responsible for the lack of statistical 
differences.24
Side effects
The first Phase II clinical trial in 2005 reported adverse 
events in 56% and 60% of patients in the telavancin and 
standard therapy group, respectively. Adverse events pos-
sibly or probably related to therapy were reported for 32% 
of patients in the telavancin group and in 29% in the 
standard therapy group. Fewer patients in the telavancin 
group  experienced severe adverse events (4% versus 7% 
for the telavancin and standard therapy groups, respec-
tively).  Similar proportions of patients discontinued therapy 
because of an adverse event in both groups (6% of the 
telavancin group and 5% of the standard therapy group). 
The incidences of most adverse events were similar between 
the two groups. Three patients in the vancomycin group 
experienced red man syndrome, compared with none in the 
telavancin group. Maximum creatinine levels were 2.3 mg/
dL in the telavancin group, which occurred in two patients, 
and 2.5 mg/dL in the standard therapy group, which 
occurred in one patient. The remainder of the abnormal 
values ranged from 1.2 mg/dL to 1.8 mg/dL. The increase 
in serum creatinine levels were documented as being revers-
ible and did not lead to treatment discontinuation. Labora-
tory abnormalities included more elevated serum creatinine 
in the telavancin group than in the standard therapy group, 
and this was reversible. Microalbuminuria was found more 
commonly in patients with the telavancin group, but was 
not associated with abnormal serum creatinine levels. A 
mild decrease in platelet count (7% versus 0%) and a 
6.4 msec QT interval were observed more often in the 
telavancin group.26
The second Phase II clinical trial in 2006 reported 
adverse events in 56% and 57% in the patients who received 
telavancin and standard therapy, respectively. Among 
patients with adverse events, 73% of those in the telavancin 
group and 59% of those in the standard therapy group had 
events which were considered to be possibly or probably 
related to therapy (P = 0.16). Similar proportions of patients 
in both groups experienced severe adverse events (6% and 
4% for the telavancin and standard therapy groups, respec-
tively) or were withdrawn from the study medication due to 
an adverse event (6% in the telavancin group and 3% in the 
standard therapy group). Disseminated intravascular coagu-
lation, atrial fibrillation, gastrointestinal bleeding, lobar 
pneumonia, subcutaneous abscess, wound infection, myo-
sitis, suicidal ideation, renal failure, ileostomy, hypotension, 
and wound hemorrhage were documented in the patients 
who received telavancin. The investigators also reported 
multiorgan failure, liver failure, bacteremia, sepsis, renal 
failure, atelectasis, lung infiltrations, and respiratory failure 
in the standard therapy group. Overall, mild and transient 
nausea, insomnia, headache, and taste alterations occurred 
more frequently in patients assigned to the telavancin group. 
Two patients on telavancin therapy had rashes of moderate 
severity and were withdrawn from the study. No case of red 
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man syndrome was reported. Serum creatinine was increased 
in five patients in the telavancin group at the end of therapy. 
Maximum concentrations of serum creatinine were less than 
1.8 mg/dL in all but one patient who had another predispos-
ing medical problem and was withdrawn from the study on 
day 4. Hypokalemia was more common in the telavancin 
group. The minimum potassium value was 2.2 mEq/L, and 
all other values at end of therapy ranged from 3.4 to 
3.5 mEq/L. The occurrence of hypomagnesemia and 
microalbuminuria was similar in both groups. Alteration in 
liver function tests and eosinophilia were less common 
among patients who received telavancin. According to an 
analysis of electrocardiographic data, a 12.5 msec longer 
Fridericia corrected QT interval was seen in the telavancin 
group (P # 0.0001). In addition, more corrected QT outliers 
were noted in the telavancin patients (6%) compared with 
those on standard therapy (1%). There were no cardiac 
adverse events reported to be associated with corrected QT 
prolongation.27
In 2008, Strijewski et al documented adverse events in 
79% and 72% of patients who received telavancin and van-
comycin, respectively, in their Phase III trial. The incidence 
of serious adverse events was higher in the telavancin group 
than in the vancomycin group (7% versus 4%, respectively). 
Slightly more patients discontinued telavancin therapy than 
vancomycin therapy (8% versus 6%). Except for taste 
 disturbance, mild nausea, vomiting, and foaming urine in 
the telavancin group (33%, 27%, 14%, and 13% for telavan-
cin therapy versus 7%, 15%, 13%, and 3% for the vanco-
mycin group), adverse events were similar in type and 
severity between the groups. Taste disturbance was transient 
in the telavancin group, and was usually described as a 
metallic or soapy taste. Nausea and vomiting were mild. 
Individual serious adverse events and adverse events leading 
to discontinuation occurred in less than 1% in both treatment 
groups. Serum creatinine levels were increased by more than 
1.5 mg/dL and more than 50% above the baseline level 
in 6% and 2% of patients in the telavancin and vancomycin 
groups, respectively. In all patients, serum creatinine con-
centrations returned to baseline values or were resolving at 
test-of-cure. One patient experienced temporary mild hear-
ing loss with telavancin treatment. Renal dysfunction 
occurred in 3% of patients in the telavancin group and in 
1% of patients who received vancomycin, and serum crea-
tinine concentrations returned to baseline values during the 
follow-up period. Less than 1% of the patients discontinued 
the study because of renal adverse events. An analysis of 
electrocardiographic data revealed that corrected QT 
interval outliers (QTc interval  prolonged .60 msec) 
occurred with similar frequency in both groups. One patient 
in the telavancin group and two patients in the vancomycin 
group had a corrected QT interval .500 msec during the 
study. No cardiac adverse events were associated with cor-
rected QT interval prolongation. Other adverse events in both 
telavancin and vancomycin therapy groups included insomnia, 
constipation, diarrhea, dizziness, rash, infusion site pain, 
fatigue, chills, general pruritus, infusion site erythema, 
decreased appetite, anxiety, renal dysfunction, and abdominal 
pain.16,48
Conclusion
In summary, increasing resistance rates, acquisition in the 
community, and the emergence of more virulent strains have 
transformed MRSA into a major global health problem. In 
addition, intermediately vancomycin-susceptible S. aureus 
and even S. aureus fully resistant to vancomycin have been 
clinically documented.
Telavancin has a more potent bactericidal effect against 
MSSA and MRSA than do the beta-lactams, linezolid and 
vancomycin. In patients infected with MRSA, treatment 
with telavancin produced significantly higher bacterial 
eradication rates at test-of-cure than vancomycin (92% 
versus 68%, P = 0.04). Telavancin was four times more 
potent in vitro than vancomycin against the clinical strains 
of MRSA isolated during the study (MIC
90
, 0.25 µg/mL 
for telavancin versus 1.0 µg/mL for vancomycin). More 
importantly, telavancin achieved peak concentrations in 
serum more than 300-fold higher than the MIC
90
 for 
MRSA. Telavancin 10 mg/kg achieved higher clinical and 
microbiological response rates than telavancin 7.5 mg/kg, 
which may at least in part be explained by its concentration-
dependent bactericidal effects. Telavancin 10 mg/kg once 
daily is at least as effective as vancomycin twice daily for 
the treatment of the patients with complicated skin and 
soft tissue infections, and would be particularly useful for 
S. aureus strains exhibiting an increased MIC to vancomy-
cin. Overall, the frequencies of adverse events were similar 
in the telavancin and vancomycin groups. Evaluation of 
serum creatinine levels at baseline and repeated after 
48–72 hours of treatment is recommended. The advantages 
of using telavancin include once-daily dosing, shorter 
duration of treatment, and no requirement for monitoring 
of serum levels. The potential use of telavancin could be 
for recurrence of MRSA in complicated skin and soft tissue 
infections which have already been treated with 
vancomycin.
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